Literature DB >> 3986984

Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure.

E S Monrad, D S Baim, H S Smith, A Lanoue, E Brauwald, W Grossman.   

Abstract

To examine the effect of milrinone on myocardial energetics in patients with congestive heart failure, we measured systemic, pulmonary, and coronary hemodynamics in 18 patients before and after intravenous administration of milrinone (125 +/- 36 micrograms/kg). There was a 45% increase in cardiac index (2.1 +/- 0.5 to 3.0 +/- 0.6 liters/min/m2; p = .0001), a 39% fall in the pulmonary capillary wedge pressure (28 +/- 8 to 17 +/- 8 mm Hg; p = .0001), and a 42% increase in left ventricular external work (3758 +/- 1419 to 5340 +/- 1598 g-m/min; p = .0001). Both the heart rate-blood pressure product (9624 +/- 2272 to 9380 +/- 2428 mm Hg-beats/min; p = NS) and regional left ventricular myocardial oxygen consumption (7.6 +/- 2.9 to 8.1 +/- 3.1 ml O2/min; p = NS) were unchanged after milrinone, resulting in a 45% increase in calculated left ventricular external efficiency (p = .004). Although myocardial oxygen consumption did not change, regional great cardiac venous blood flow increased significantly (73 +/- 32 to 85 +/- 34 ml/min; p = .02) as a result of a 30% reduction in regional coronary vascular resistance (1.32 +/- 0.99 to 0.93 +/- 0.54 mm Hg-min/ml; p = .004), a decrease comparable to the concurrent 37% and 38% falls seen in systemic and pulmonary vascular resistance, respectively. These changes were associated with an 11% fall in the transcoronary arterial-venous oxygen difference (111 +/- 24 to 99 +/- 21 ml/O2/liter; p = .0001), which is consistent with a primary coronary vasodilator effect of milrinone.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3986984     DOI: 10.1161/01.cir.71.5.972

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

1.  Effect of olprinone, a phosphodiesterase III inhibitor, on arterial wall distensibility: differentiation between aorta and common carotid artery.

Authors:  M Seki; K Mizushige; T Ueda; M Kitadai; H Matsuo
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

2.  Myocardial oxidative metabolic supply-demand relationships in patients with nonischemic dilated cardiomyopathy.

Authors:  Marvin W Kronenberg; Gerald I Cohen; Marlo F Leonen; Thomas A Mladsi; Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2006-07       Impact factor: 5.952

Review 3.  Adverse effects associated with the newer inotropic agents.

Authors:  M W Webster; D N Sharpe
Journal:  Med Toxicol       Date:  1986 Sep-Oct

Review 4.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

Review 5.  Milrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  R A Young; A Ward
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 6.  Studies on the mechanism of action of the bipyridine milrinone on the heart.

Authors:  A E Farah; C J Frangakis
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

7.  Additive positive inotropic effects of milrinone, ouabain and calcium in diseased human ventricular myocardium.

Authors:  L Brown; M Näbauer; E Erdmann
Journal:  Klin Wochenschr       Date:  1986-08-01

8.  Dose-response effects of milrinone on hemodynamics of newborn pigs with hypoxia-reoxygenation.

Authors:  Chloë Joynt; David L Bigam; Gregory Charrois; Laurence D Jewell; Gregory Korbutt; Po-Yin Cheung
Journal:  Intensive Care Med       Date:  2008-03-21       Impact factor: 17.440

Review 9.  Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.

Authors:  T A Fischer; R Erbel; N Treese
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

Review 10.  Intravenous vasodilator therapy in congestive heart failure.

Authors:  Kourosh Moazemi; Jatinder S Chana; Anna Marie Willard; Abraham G Kocheril
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.